Delivery Order SPE2DB24D1205-SPE2DB25FCZEZ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,112.15 for SKYRIZI 150 mg/mL pen injectors under a firm fixed price, non-competitive contract structure. The award was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and performance will be conducted at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle. This...
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a $32,614.21 delivery order to AmerisourceBergen Drug Corp for Skyrizi 150 mg/ml pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,788.01 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 180 mg/1.2 ml on-body injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price contract represents a competitively awarded, non-set-aside procurement of the pharmaceutical product to support federal medical supply requirements. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $11,830 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 ml on-body injectors on July 29, 2025, with completion targeted for August 19, 2025. This non-set-aside award represents a supply of a specialized biologic medication used primarily for dermatological and rheumatological conditions. The delivery order was issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on July 24, 2025, for SKYRIZI 150 mg/mL pens valued at $17,794.40 under a firm fixed price arrangement. This non-set-aside award is scheduled for completion by July 25, 2025, with delivery performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZEZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors, with a ceiling value of $39,734.36 and a firm fixed price structure. This is a non-set-aside competitive award under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location and will complete delivery by August 5, 2025. This delivery order represents a routine pharmaceutical procurement through DLA's Medical Supply Chain, which leverages AmerisourceBergen's capabilities as a major pharmaceutical distributor serving federal healthcare systems including the Defense Health Agency and U.S. Coast Guard. The SPE2DX IDC serves as the prime contract vehicle enabling AmerisourceBergen to supply a comprehensive range of pharmaceutical products, medical devices, and specialty medications to support military healthcare operations globally. The company's selection through open competition reflects its established capability to meet federal medical procurement requirements and aligns with DLA's strategy to maintain multiple prime vendors across regions for pharmaceutical supply under its evolving Pharmaceutical Prime Vendor Global Program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.7k | 8/4/25 |